| |
|
|
|
Summit Therapeutics plc  
|
|
3.42 0.08 (0.02%) |
09-18 16:00 |
|
Open: |
3.4 |
Pre close: |
3.34 |
Target:
|
4.15
|
|
High: |
3.46 |
Low: |
3.24 |
Resistance:
|
3.55
3.80
|
|
Volume: |
19,723 |
Market Cap: |
230M |
Support:
|
3.15
2.62
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.32
 |
MACD |
MACD(12,26):
|
-0.06 |
|
MA(20): |
3.41  |
Signal(12,26,9): |
-0.06 |
|
MA(100): |
3.48 |
Stochastic Oscillator |
%K(14,3):
|
51.67 |
|
MA(250): |
2.51 |
%D(3): |
37.07 |
|
Average Volume(K) |
3-Month: |
6455
|
52-Week |
High:
|
5.49 |
|
10-Days: |
2553 |
Low: |
1.18 |
|
RSI |
RSI(14):
|
50.51 |
Change(%): |
139.2 |
|
Financials, Statistics and Valuation |
|
EPS |
1.225 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
67.23 |
|
EPS Est. Current Year |
-0.530 |
Return on Assets (ttm) |
0.0 |
Shares Float (M) |
24.81 |
|
EPS Est. Next Year |
-1.050 |
PEG Ratio |
0.00 |
% Held by Insiders |
23.29 |
|
EPS Est. Next Quarter |
-0.620 |
Qtrly Rev. Growth |
-12.2 |
% Held by Institutions |
8.53 |
|
Forward EPS |
0.118 |
Gross Profit (p.s.) |
0.256 |
Shares Short (K) |
53 |
|
Book Value (p.s.) |
2.260 |
EBITDA (p.s.) |
0.000 |
P/E |
2.79 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
1.51 |
|
Profit Margin |
-142.60 |
Operating Cash Flow
(M) |
0.00 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
0.00 |
|
|
|
|
|
|
